↑ Rising
Business
US FDA declines to approve Capricor's Duchenne treatment citing unreliable trial data; shares slump
6sources
6articles
18velocity
+31%since first seen
24m agofirst detected
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Coverage (6)
- Capricor Therapeutics Receives FDA Complete Response Letter for Deramiocel BLA in Duchenne Muscular Dystrophy Quiver Quantitative · 2h ago
- Key facts: FDA Extends Deramiocel Review; Capricor Reports Q3 Loss TradingView · 2h ago
- Capricor Gets Second FDA Rejection for Muscular Dystrophy Drug Bloomberg.com · 2h ago
- CAPR Stock Gains Ahead Of Weekend FDA Deramiocel Decision After Rough Week Yahoo Finance · 2h ago
- FDA rejects Capricor Therapeutics' Duchenne therapy, a decision that was a long time coming STAT · 2h ago
- US FDA declines to approve Capricor's Duchenne treatment citing unreliable trial data; shares slump Reuters · 2h ago
Related trends
▲ Peaking
Business
Nvidia stock plunges 14%, wraps up longest weekly losing streak since 2008 financial crisis
▲ Peaking
Business
AI tech rout prompts US investors to rush into value stocks
▲ Peaking
Business
Skip the junk: What retail experts say is actually worth buying on Black Friday
▲ Peaking
Business
Trump FCC declares California isn’t allowed to enforce phone service rules
▲ Peaking
Business
Your Favorite THC Drinks Are About to Be Illegal
▲ Peaking
Business